Description
News release from the UMB School of Medicine announcing the SOM's participation in a phase 3 clinical trial of a COVID-19 vaccine developed by biotechnology company, Novavax, Inc., based in Gaithersburg, MD.Keyword
Coronavirus Disease 2019 (COVID-19)Novavax, Inc.
COVID-19 (Disease)
University of Maryland, Baltimore. School of Medicine
COVID-19
COVID-19 Vaccines